Cyclodextrins in nasal delivery of low-molecular-weight heparins: In vivo and in vitro studies

Pharmaceutical Research

Volumn 21, Issue 7, 2004, Pages 1127-1136

  Yang, Tianzhi ^a   Hussain, Alamdar ^a   Paulson, Jennifer ^a   Abbruscato, Thomas J ^a   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

bioavailability; cyclodextrins; enoxaparin; low molecular weight heparin; nasal absorption; reversibility; TEER; tight junctions; transport studies

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CYCLODEXTRIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; MANNITOL; METHYL BETA CYCLODEXTRIN; PROTEIN ZO1;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG TRANSPORT; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NOSE; PLASMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; TIME;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTITHROMBIN III; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CELL EXTRACTS; CELLS, CULTURED; DALTEPARIN; ELECTRIC CONDUCTIVITY; ENOXAPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MANNITOL; MEMBRANE PROTEINS; NASAL MUCOSA; PHOSPHOPROTEINS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 3242673511     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000032998.84488.7a     Document Type: Article

References (31)

1. Y. W. Chien, K. S. E. Su, and S. Chang. Nasal systemic drug delivery, 1st Ed. Marcel Dekker, New York, 1989.
2. C. R. Behl, H. K. Pimplaskar, A. P. Sileno, W. J. Xia, W. J. Gries, J. C. deMeireles, and V. D. Romeo. Optimization of systemic nasal drug delivery with pharmaceutical excipients. Adv. Drug Del. Rev 29:117-133 (1998).
3. M. I. Ugwoke, N. Verbeke, and R. Kinget. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 53:3-22 (2001).
4. T. Irie, K. Wakamatsu, H. Arima, H. Aritomi, and K. Uekama. Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int. J. Pharm. 84:129-139 (1992).
5. K. Matsubara, K. Abe, T. Irie, and K. Uekama. Im provement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. J. Pharm. Sci. 84:1295-1300 (1995).
6. Y. Watanabe, Y. Matsumoto, K. Kawamoto, S. Yazawa, and M. Matsumoto. Enhancing effects of cyclodextrins on nasal absorption of insulin and its duration in rabbits. Chem. Pharm. Bull. 40:3100-3104 (1992).
7. E. Marttin, J. C. Verhoef, and F. W. H. M. Merkus. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J. Drug Target. 6:17-36 (1998).
8. R. I. Shulman. Assessment of low-molecular-weight heparin trials in cardiology. Pharm. Ther. 87:1-9 (2000).
9. J. J. Arnold, F. Ahsan, E. Meezan, and D. J. Pillion. Nasal administration of low molecular weight heparin. J. Pharm. Sci. 91:1707-1714 (2002).
10. P. Augustijns, P. Annaert, P. Heylen, G. Van den Mooter, and R. Kinget. Drug absorption studies of prodrug ester using the Caco2 model: evaluation of ester hydrolysis and transepithelial transport. Int. J. Pharm. 166:45-53 (1998).
11. J. Fareed, F. Kaiding, L. H. Yang, and D. A. Hoppensteadt. Pharmacokinetics of low molecular weight heparins in animal models. Semin. Thromb. Hemost. 25:51-55 (1999).
12. L. Bara and M. Samama. Pharmacokinetics of low molecular weight heparin. Acta Chir. Scand. Suppl. 543:65-72 (1988).
13. -). Eur. J. Pharm. Sci. 20:27-34 (2003).
14. C. Meaney, B. I. Florea, C. Ehrhardt, U. F. Schäfer, C. Lehr, H. E. Junginger, and G. Borchard. Bronchial epithelial cell cultures. In C. Lehr (ed.), Cell Culture Models of Biological Barriers, In-Vitro Test Systems for Drug Absorption and Delivery, 1st Ed., Taylor and Francis, New York, 2002, pp. 211-227.
15. T. J. Abbruscato, S. P. Lopez, K. S. Mark, B. T. Hawkins, and T. P. Davis. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J. Pharm. Sci. 91:2525-2538 (2002).
16. F. W. H. M. Merkus, N. G. M. Schipper, W. A. J. J. Hermens, S. G. Romeijn, and J. C. Verhoef. Absorption enhancers in nasal drug delivery: efficacy and safety. J. Controlled Release 24:201-208 (1993).
17. Physician's Desk Reference. Medical Economic Company Inc., Montvale, NJ, 2002.
18. E. Marttin, N. G. M. Schipper, J. C. Verhoef, and F. W. H. M. Merkus. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv. Drug Del. Rev. 29:13-38 (1998).
19. W. A. J. J. Hermens, C. W. J. Belder, J. M. W. M. Merkus, P. M. Hooymans, J. Verhoef, and F. W. H. M. Merkus. Intranasal estradiol administration to oophorectomized women. Eur. J. Obstet. Gynecol. Reprod. Biol. 40:35-41 (1991).
20. W. A. J. J. Hermens, C. W. J. Belder, J. M. W. M. Merkus, P. M. Hooymans, J. Verhoef, and F. W. H. M. Merkus. Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 43:65-70 (1992).
21. K. Asai, M. Morishita, H. Datsuta, S. Hosoda, K. Shinomiya, M. Noro, T. Nagai, and K. Takayama. The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. Int. J. Pharm. 246:25-35 (2002).
22. N. Haffejee, J. D. Plessis, D. G. Muller, C. Schultz, A. F. Kotze, and C. Goosen. Intranasal toxicity of selected absorption enhancers. Pharmazie 56:882-888 (2001).
23. N. Washington, C. Washington, and C. G. Wilson. Physiological Pharmaceutics (Barriers to Drug Absorption), 2nd Ed., Taylor and Francis, New York, 2001, pp. 225.
24. J. L. Devalia and R. J. Davies. Human nasal and bronchial epithelial cells in culture: an overview of their characteristics and function. Allergy Proc. 12:71-79 (1991).
25. S. T. Lim, G. P. Martin, M. B. Brown. In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate. AAPS Pharmsci. Tech. 2(4): article 20 (2001). http://www.pharmscitech.com.
26. L. Hovagaard and H. Brondsted. Drug delivery studies in Caco-2 monolayer. IV. Absorption enhancer effects of cyclodextrins. Pharm. Res. 12:1328-1332 (1995).
27. Z. Shao, R. Krishnamoorthy, and A. K. Mitra. Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations. Pharm. Res. 9:1157-1163 (1992).
28. E. Marttin, J. C. Verhoef, S. G. Romeijn, and F. W. H. M. Merkus. Effects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharm. Res. 12:1151-1157 (1995).
29. L. Szente, and J. Szejtli. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Del. Rev. 36:17-28 (1999).
30. K. Uekama and M. Otagiri. Cyclodextrins in drug carrier systems. CRC Crit. Rev. Ther. Drug Carrier Syst. 3:1-40 (1987).
31. E. Marttin and J. C. Verhoef, C Cullander, S. G. Romeijn, J. F. Nagelkerke and F. W. H. M. Merkus. Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: effects of absorption enhancers. Pharm. Res. 14:631-637 (1997).